TSX Venture: QPT
EDMONTON, May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
SL052 is an injectible, synthetic derivative of a small molecular weight compound called Hypocrellin, which is isolated from a parasitic fungus that grows on bamboo trees in China. In Quest's Phase I trial, SL052 is inactive in a patient's body until activated by laser light of specific wavelength. Upon light activation, oxygen radicals are formed which are known to be toxic to tumor cells. This method of treatment is known as photodynamic therapy or PDT.
"SL052 photodynamic therapy is a promising treatment modality for prostate cancer because of its potential to minimize collateral damage compared to conventional treatment approaches," said Dr. Madi R. Madiyalakan, Quest's Chief Executive Officer. "In preclinical trials, SL052 photodynamic therapy demonstrated an impressive safety and efficacy profile. In this Phase I trial, our goal is to establish a safe and tolerable dosing regime of SL052 photodynamic therapy and monitor the patients for signals of efficacy."
The clinical trial is being conducted in two stages. In the first stage, up to six patients undergoing radical prostatectomy will be enrolled to study the prostate specific localization
|SOURCE Quest PharmaTech Inc.|
Copyright©2010 PR Newswire.
All rights reserved